AI주식인사이트AI Stock Insight
C

SK바이오사이언스

302440KOSPI

48.0 / 100

Reference Date: 2026-10-23

Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 5.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

SK Bioscience, established in 2018 as a spin-off from SK Chemicals, focuses on vaccine development and global CDMO services. Key products include cell-culture influenza vaccines like 'SkyCellflu' and the COVID-19 vaccine 'SkyCovion,' which received WHO PQ certification and global approvals. The company also provides CDMO services, collaborating with global pharmaceutical firms to produce and develop vaccines.

Number of Employees

1,129people

Average Salary

67.8M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
1.33Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
-2.77Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
29.06Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲57.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼522.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -1.4% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 34,500Won52-week high 60,10052-week low 32,500
1-month return2.0Point

1m -5.09% (slight drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0